Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at
Wall St